Brief: LPCN 1148 Phase 2 Study Meets Primary Endpoint In Patients With Cirrhosis

Lipocine

27/07/2023 11:44

July 27 (Reuters) - Lipocine Inc  LPCN.O :
    * LPCN 1148 PHASE 2 STUDY MEETS PRIMARY ENDPOINT IN PATIENTS
WITH
CIRRHOSIS
    * LIPOCINE INC - FEWER HEPATIC ENCEPHALOPATHY (HE) EVENTS OF
GRADE
>1 IN LPCN 1148 TREATMENT ARM RELATIVE TO PLACEBO
    * LIPOCINE INC - MORE PATIENTS ON LPCN 1148 REPORTED SYMPTOM
IMPROVEMENT COMPARED TO PLACEBO
    * LIPOCINE INC - LPCN 1148 WAS WELL-TOLERATED, WITH AE RATES
AND
SEVERITIES SIMILAR TO PLACEBO
    * LIPOCINE INC - PLANS TO MEET WITH FDA TO DISCUSS A
DEVELOPMENT
PATH TO NDA FILING

Source text for Eikon:  ID:nPn1BTpRja 
Further company coverage:  LPCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))